ライフサイエンスコーパス: or death

1 omposite end point of brain damage, nursing home admission, or death (hazard ratio, 0.67; 95% CI, 0.53 to 0.84).

2 ome was a composite of repeat ED visit, hospital admission, or death within 7 days of discharge.

3 ease progression or the development of a new primary cancer or death assessed at 4.5 years after randomization.

4 me from randomization to recurrence, second primary cancer, or death.

5 Severe hypoglycemia can lead to coma or death.

6 systematic dysphagia screening and follow-up until 90 days or death.

7 n the United States and may lead to a range of disabilities or death.

8 ention and that led (or could have led) to major disability or death.

9 We determined type, severity, outcome (disability or death), and time course of bleeding requiring medical atte

10 dpoint was time to progression (time of progressive disease or death from any cause), with intention-to-treat analysis.

11 , confirmed by a cardiologist, and a significant LVEF drop, or death of definite or probable cardiac causes.

12 ome; and a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103 patients wh

13 The primary outcome was a composite of long-term CV events or death, which was assessed via national health care databas

14 iation with the combined outcome of new neurological events or death (HR, 1.58 [95% CI, 1.11-2.23]).

15 malignant ventricular arrhythmias, end-stage heart failure, or death) compared with carriers of other pathogenic LMNA mut

16 ed to predict myocardial infarction, stroke, heart failure, or death.

17 with LBBB randomized to CRT-D, there were differences in HF or death risk and in the degree of reverse remodeling among c

18 e risk discrimination of diastolic measures for incident HF or death.

19 sociated with a greater risk of incident HF hospitalization or death at a median follow-up of 608 days.

20 brain natriuretic peptide and subsequent HF hospitalization or death.

21 d hazard ratios (HRs) of death and of AIDS-defining illness or death, risk ratios of virological failure, and mean differ

22 isease, defined as the first incident myocardial infarction or death owing to coronary heart disease, and stroke, defined

23 as the time to occurrence of stroke, myocardial infarction, or death within 90 days.

24 lated from time of exposure to the occurrence of meningioma or death or until December 31, 2010, with logistic regression

25 composite outcome of respiratory or neurosensory morbidity or death after discharge.

26 ed self-righting can result in loss of mating opportunities or death.

27 ignificant change in the incidence of the composite outcome or death-censored cardiovascular events over time (P = 0.41 a

28 ths versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001).

29 s. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001).

30 Secondary end points included time to second progression or death, toxic effects, and quality of life.

31 Time to readmission or death within 12 months adjusted for the number of previous

32 on to home oxygen therapy prolonged the time to readmission or death within 12 months.

33 transfusion, therapeutic intervention, 28 day readmission, or death.

34 geneity was associated with an increased risk of recurrence or death (hazard ratio, 4.9; P=4.4x10(-4)), which remained si

35 ability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chro

36 The risk factors for relapse or death after initial recovery were a smaller midupper arm c

37 roup and 39% in the placebo group (hazard ratio for relapse or death, 0.47; 95% confidence interval [CI], 0.39 to 0.58; P

38 settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage diseas

39 cal progression of cancer from low to moderate or high risk or death during 24 months' follow-up) and absence of definite

40 a under the curve, 0.78) and the combined end point of RVAD or death within 14 days (area under the curve, 0.73).

41 rs for RVAD implantation and the combined end point of RVAD or death within 14 days of LVAD were assessed with stepwise l

42 t disease, and stroke, defined as the first nonfatal stroke or death owing to stroke.

43 es: Incident CVD, including coronary heart disease, stroke, or death from cardiovascular causes.

44 end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death.

45 Data for all patients were censored 1 year post-study or death, whichever came first.

46 d, different Tolls can preferentially promote cell survival or death.

47 c renal failure, involvement of the central nervous system, or death), and interventions (ie, renal replacement therapy).

48 sk Triage score were calculated for predicting ICU transfer or death within 48 hours of meeting suspicion criteria.

49 iation of mechanical circulatory support, heart transplant, or death.

50 rk of interactions leading to either clearance of the virus or death of the host, depending on the initial dosage of the